• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B filed by Cybin Inc.

    1/2/26 6:14:27 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYBN alert in real time by email
    8-A12B 1 form8a12b.htm FORM 8-A12B Cybin Inc.: Form 8-A12B - Filed by newsfilecorp.com

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    FORM 8-A


    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR (g) OF

    THE SECURITIES EXCHANGE ACT OF 1934


    CYBIN INC.

    (Exact name of registrant as specified in its charter)



    Ontario

    N/A

    (State of incorporation or organization)

    (I.R.S. Employer Identification No.)


    100 King Street West, Suite 5600, Toronto,

    Ontario, Canada

    M5X 1C9

    (Address of principal executive offices)

    (Zip Code)

    Securities to be registered pursuant to Section 12(b) of the Act:

    Title of each class

    to be so registered

    Name of each exchange on which

    each class is to be registered

    Common Shares, no par value

    The Nasdaq Stock Market LLC



    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐


    Securities Act registration statement or Regulation A offering statement file number to which this form relates:

    Not applicable

    Securities to be registered pursuant to Section 12(g) of the Act:

    None


    EXPLANATORY NOTE

    Cybin Inc. (the "Registrant") is filing this Form 8-A in connection with the transfer of the listing of its common shares (the "Common Shares") from the NYSE American LLC ("NYSE American") to the Nasdaq Stock Market LLC ("Nasdaq"). The Registrant expects that listing and trading of the Common Shares on the NYSE American will end at market close on January 2, 2026, and that trading will begin on the Nasdaq at market open on January 5, 2026.

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 1. Description of Registrant's Securities to be Registered.

    For a description of the Common Shares of the Registrant to be registered hereunder, reference is made to the information set forth under the heading "Description of Capital Structure", as it relates to the Registrant's Common Shares, in the Registrant's annual report filed as Exhibit 99.1 to the Registrant's Annual Report for the year ended March 31, 2024 on Form 40-F (File No. 001-40673) filed with the Commission on July 1, 2025, which information is incorporated by reference herein.

    Item 2. Exhibits.

    Under the Instructions as to Exhibits in Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on the Nasdaq and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.


    SIGNATURE

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

      CYBIN INC.
         
    Date: January 2, 2026 By: /s/ Greg Cavers
        Name: Greg Cavers
    Title: Chief Financial Officer


    Get the next $CYBN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYBN

    DatePrice TargetRatingAnalyst
    3/13/2025$35.00Buy
    Guggenheim
    11/22/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    11/19/2021Buy → Hold
    Maxim Group
    10/5/2021$7.00Outperform
    Oppenheimer
    8/26/2021$9.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CYBN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq

    Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company's ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market ("Nasdaq") and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists ("NSAs"), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma's NSA in Phase 3 clinical development,

    1/5/26 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Initiates At-The-Market Equity Program of up to US$100 Million

    Cybin Inc. (NYSE:CYBN) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has launched an at-the-market equity program (the "ATM Program") to allow Cybin to issue and sell up to US$100,000,000 of common shares in the capital of the Company (the "Shares") from treasury to the public, from time to time, through Cantor Fitzgerald and Co. and Cantor Fitzgerald Canada Corporation (together the "Agents"). All the Shares sold under the ATM Program will be sold in transactions that are deemed to be "at-the-market

    12/30/25 3:33:00 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

    Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market ("Nasdaq") from the NYSE American LLC ("NYSE American"). The Company expects that its common shares will cease trading on the NYSE American at market close on January 4, 2026 and commence trading on Nasdaq at market open on January 5, 2026. Concurrent with the commencement of trading on Nasdaq, the Company will no longer trade under the ticker symbol "CYBN" and instead will trade under

    12/18/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    SEC Filings

    View All

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    1/5/26 4:51:28 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form CERT filed by Cybin Inc.

    CERT - CYBIN INC. (0001833141) (Filer)

    1/2/26 11:06:32 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-A12B filed by Cybin Inc.

    8-A12B - CYBIN INC. (0001833141) (Filer)

    1/2/26 6:14:27 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Cybin with a new price target

    Guggenheim initiated coverage of Cybin with a rating of Buy and set a new price target of $35.00

    3/13/25 7:34:44 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Cybin with a new price target

    HC Wainwright & Co. reiterated coverage of Cybin with a rating of Buy and set a new price target of $10.00 from $8.00 previously

    11/22/21 6:24:49 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin downgraded by Maxim Group

    Maxim Group downgraded Cybin from Buy to Hold

    11/19/21 8:09:52 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    Leadership Updates

    Live Leadership Updates

    View All

    Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

    Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market ("Nasdaq") from the NYSE American LLC ("NYSE American"). The Company expects that its common shares will cease trading on the NYSE American at market close on January 4, 2026 and commence trading on Nasdaq at market open on January 5, 2026. Concurrent with the commencement of trading on Nasdaq, the Company will no longer trade under the ticker symbol "CYBN" and instead will trade under

    12/18/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Announces Results of Annual Meeting of Shareholders

    Cybin Inc. (NYSE:CYBN) (Cboe CA: CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the "Meeting"). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below:

    8/18/25 5:30:00 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

    - Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment - - Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of MDD patients - - Patient dosing continues in APPROACH, Cybin's first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder ("MDD") - - Second Phase 3 study, EMBRACE, is expected to begin mid-2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform

    4/23/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    Financials

    Live finance-specific insights

    View All

    Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

    - Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. CONFERENCE CALL DETAILS: Dial-in: 800-245-3047 (U.S. toll free) or 203-518-9765 (International) Conference ID: CYBN1113 Webcast: R

    11/6/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

    - 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared to baseline at 12 months after two 16 mg doses of CYB003 - - Findings validate dosing regimen and confirm that CYB003's effects are highly durable and offer sustained relief for MDD patients - - CYB003 continues to be well-tolerated and demonstrates an excellent safety profile - - Cybin's Phase 3 PARADIGM TM multinational pivotal program evaluating the efficacy and safety of CYB003 has been initiated - - Company to

    11/18/24 7:00:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

    - Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 - - Presentation will also include discussion of its recently initiated Phase 3 PARADIGM program for CYB003 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET. The event will be hosted by Cybin's Chief Executive Officer, Doug Drysdale, and Cybin's Chief Medical Officer, Amir Inamdar, and will incl

    11/14/24 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cybin Inc.

    SC 13G - CYBIN INC. (0001833141) (Subject)

    12/3/24 5:23:26 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cybin Inc.

    SC 13G/A - CYBIN INC. (0001833141) (Subject)

    11/14/24 7:51:22 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cybin Inc.

    SC 13G/A - CYBIN INC. (0001833141) (Subject)

    11/14/24 6:55:13 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care